The European LeukemiaNet: achievements and perspectives
暂无分享,去创建一个
P. Schrotz-King | H. Döhner | H. Einsele | H. Dombret | R. Foà | M. Baccarani | T. Barbui | U. Mansmann | M. Hallek | M. Béné | A. Gratwohl | D. Niederwieser | C. Haferlach | C. Fonatsch | M. Sanz | G. Barosi | D. Grimwade | H. Serve | G. Ossenkoppele | P. Ljungman | T. Büchner | R. Hehlmann | B. Labar | J. Ribera | A. Hochhaus | F. Guilhot | A. Burnett | U. Berger | H. Rieder | D. Hoelzer | J. Apperley | R. Bassan | N. Gökbuget | B. Simonsson | J. Hasford | S. Saussele | E. Gluckman | J. Kiladjian | T. Haferlach | G. Engelich | T. D. de Witte | Nicolas C P Cross
[1] 黄亚明(整理),et al. ICMJE , 2012 .
[2] M. Griesshammer,et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] T. Barbui,et al. JAK2V617F Mutation Persists IN Blasts and Mature CELLS of Transformed- JAK2V617F-POSITIVE-MYELOPROLIFERATIVE Neoplasia: A European LEUKEMIA NET (ENL) STUDY , 2010 .
[4] T. Barbui,et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. , 2010, Blood.
[5] S. Shurtleff,et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] T. Barbui,et al. JAK2V617F mutation persists in blasts and mature cells of transformedJAK2V617F‐positive‐myeloproliferative neoplasia: A European leukemia net (ENL) study , 2010, American journal of hematology.
[7] Martin C. Müller,et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. , 2010, Blood.
[8] M. Griesshammer,et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process , 2010, British journal of haematology.
[9] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[10] Jean Feuillard,et al. Four‐ and five‐color flow cytometry analysis of leukocyte differentiation pathways in normal bone marrow: A reference document based on a systematic approach by the GTLLF and GEIL , 2009, Cytometry. Part B, Clinical cytometry.
[11] J. Radich,et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] V. V. D. van der Velden,et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Brand,et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation , 2009, Cancer.
[14] N. Cross,et al. Harmonization of molecular monitoring of CML therapy in Europe , 2009, Leukemia.
[15] H. Kantarjian,et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase , 2009, Cancer.
[16] F. Lo‐Coco,et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Wolfgang Kern,et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes , 2009, Haematologica.
[18] M. Béné,et al. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet , 2009, Haematologica.
[19] M. Griesshammer,et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. , 2009, Blood.
[20] Giovanni Martinelli,et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. , 2009, Blood.
[21] H. Einsele,et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia , 2009, Bone Marrow Transplantation.
[22] A. Jones,et al. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions , 2009, Leukemia.
[23] E. Estey,et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2009, Blood.
[24] W. Hiddemann,et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] K. Rezvani,et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. , 2008, Blood.
[26] Torsten Haferlach,et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase , 2008, British journal of haematology.
[27] H. Einsele,et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.
[28] Michael Hallek,et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.
[29] Andreas Hochhaus,et al. Chronic myeloid leukaemia , 2007, The Lancet.
[30] L. Leibovici,et al. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients , 2007 .
[31] C. Lass‐Flörl,et al. Primary antifungal prophylaxis in leukaemia patients , 2007 .
[32] T. Calandra,et al. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever , 2007 .
[33] A. Thiébaut,et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients , 2007 .
[34] M. Rondoni,et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2007, Blood.
[35] B. Johansson,et al. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes , 2007, Genes, chromosomes & cancer.
[36] J. Byrd,et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.
[37] K. Stamatopoulos,et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia , 2007, Leukemia.
[38] E. Kimby,et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus , 2007, Leukemia.
[39] J. Moake,et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. , 2007, Haematologica.
[40] Francisco Cervantes,et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. , 2006, Blood.
[41] J. Goldman,et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia , 2006, Leukemia.
[42] T Haferlach,et al. Consensus guidelines for microarray gene expression analyses in leukemia from three European leukemia networks , 2006, Leukemia.
[43] Simona Soverini,et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. , 2006, Blood.
[44] J. Sierra,et al. The role of stem cell source in autologous hematopoietic stem cell transplantation for patients with myelodysplastic syndromes. , 2006, Haematologica.
[45] H. Einsele,et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT , 2005, Bone Marrow Transplantation.
[46] W. Hiddemann,et al. The German competence network ‘Acute and chronic leukemias’ , 2004, Leukemia.